Data News > Nasdaq News Roundup: AxiomSL Revenue Change, Inducement Grants, Registered Direct Offering, and Stock Performance
- Nasdaq to discuss accounting treatment change for AxiomSL revenues
- Arcutis Biotherapeutics approves inducement grants for new employees
- Eastside Distilling announces $0.4 million registered direct offering
- Nasdaq stock sees a 42.5% rally in a year
- Adverum Biotechnologies grants stock options and RSUs under Nasdaq rules
Nasdaq, Inc. has organized a teach-in session to address the modification in revenue recognition for AxiomSL on-premises subscription contracts. This adjustment, which was mentioned during Nasdaq's second quarter earnings announcement, will have financial effects consistent with previous disclosures.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, recently granted 37,000 restricted stock units of the company's common stock to three newly hired employees. These awards, approved by the Compensation Committee, were issued under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
Eastside Distilling, known for its craft-inspired experiential brands, disclosed a registered direct offering totaling $0.4 million. This offering involved the sale and issuance of 442,042 shares of the company's common stock to a single institutional investor at a unit purchase price of $1.00, following Nasdaq rules.
The stock of Nasdaq has experienced a significant 42.5% rise over the past year. This increase is attributed to the company's strong organic growth, strategic acquisitions to tap into expanding market opportunities, and effective capital deployment strategies.
Adverum Biotechnologies granted inducement awards to three new employees, including non-qualified stock options and restricted stock units (RSUs). These awards were approved by the Compensation Committee under the company's 2017 Inducement Plan in adherence to Nasdaq Listing Rule 5635(c)(4).
In addition to these announcements, RedHill Biopharma has regained compliance with Nasdaq's minimum bid price requirement. Meanwhile, the S&P 500 and Nasdaq experienced a second consecutive decline, with the CNN Money Fear and Greed index indicating a "Neutral" market sentiment.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Nasdaq News Roundup: AxiomSL Revenue Change, Inducement Grants, Registered Direct Offering, and Stock Performance
By KlickAnalytics Data Insights | September 5, 2024 08:07PM ET
Key Points
- Nasdaq to discuss accounting treatment change for AxiomSL revenues
- Arcutis Biotherapeutics approves inducement grants for new employees
- Eastside Distilling announces $0.4 million registered direct offering
- Nasdaq stock sees a 42.5% rally in a year
- Adverum Biotechnologies grants stock options and RSUs under Nasdaq rules
Nasdaq, Inc. has organized a teach-in session to address the modification in revenue recognition for AxiomSL on-premises subscription contracts. This adjustment, which was mentioned during Nasdaq's second quarter earnings announcement, will have financial effects consistent with previous disclosures.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, recently granted 37,000 restricted stock units of the company's common stock to three newly hired employees. These awards, approved by the Compensation Committee, were issued under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
Eastside Distilling, known for its craft-inspired experiential brands, disclosed a registered direct offering totaling $0.4 million. This offering involved the sale and issuance of 442,042 shares of the company's common stock to a single institutional investor at a unit purchase price of $1.00, following Nasdaq rules.
The stock of Nasdaq has experienced a significant 42.5% rise over the past year. This increase is attributed to the company's strong organic growth, strategic acquisitions to tap into expanding market opportunities, and effective capital deployment strategies.
Adverum Biotechnologies granted inducement awards to three new employees, including non-qualified stock options and restricted stock units (RSUs). These awards were approved by the Compensation Committee under the company's 2017 Inducement Plan in adherence to Nasdaq Listing Rule 5635(c)(4).
In addition to these announcements, RedHill Biopharma has regained compliance with Nasdaq's minimum bid price requirement. Meanwhile, the S&P 500 and Nasdaq experienced a second consecutive decline, with the CNN Money Fear and Greed index indicating a "Neutral" market sentiment.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.